---
title: Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible
  Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World
  Cohort (AIO-TRK-0315)
date: '2024-04-08'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38586301/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240408180554&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: Our data reveal that a considerable proportion of patients
  with mNSCLC are not eligible to participate in a clinical trial and were found to
  have worse outcomes than potentially trial-eligible patients, whose outcomes were
  comparable with those obtained from pivotal clinical trials. This is of substantial
  clinical relevance for physicians discussing outcomes to be expected with their
  patients and stresses the need for real-world effectiveness ...'
disable_comments: true
---
CONCLUSIONS: Our data reveal that a considerable proportion of patients with mNSCLC are not eligible to participate in a clinical trial and were found to have worse outcomes than potentially trial-eligible patients, whose outcomes were comparable with those obtained from pivotal clinical trials. This is of substantial clinical relevance for physicians discussing outcomes to be expected with their patients and stresses the need for real-world effectiveness ...